Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo JASDAQ  >  RaQualia Pharma Inc.    4579   JP3967150008

RAQUALIA PHARMA INC.

(4579)
  Report
End-of-day quote. End-of-day quote Tokyo JASDAQ - 11/25
984 JPY   -2.96%
 SummaryChartsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Jasdaq
11/18/2020 11/19/2020 11/20/2020 11/24/2020 11/25/2020 Date
984 982 992 1014 984 Last
89500 70400 98500 268500 142900 Volume
+0.92% -0.20% +1.02% +2.22% -2.96% Change
Financials
Sales 2020 1 898 M 18,2 M 18,2 M
Net income 2020 153 M 1,47 M 1,47 M
Net Debt 2020 - - -
P/E ratio 2020 135x
Yield 2020 -
Sales 2021 2 010 M 19,2 M 19,2 M
Net income 2021 245 M 2,35 M 2,35 M
Net Debt 2021 - - -
P/E ratio 2021 84,5x
Yield 2021 -
Capitalization 21 244 M 203 M 203 M
Capi. / Sales 2020 11,2x
Capi. / Sales 2021 10,6x
Nbr of Employees 68
Free-Float 86,1%
More Financials
Company
RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4... 
Sector
Pharmaceuticals
Calendar
02/05Earnings Release
More about the company
All news about RAQUALIA PHARMA INC.

- No features available -

More news
News in other languages on RAQUALIA PHARMA INC.

- No features available -

More news
Chart RAQUALIA PHARMA INC.
Duration : Period :
RaQualia Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAQUALIA PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 1 900,00 JPY
Last Close Price 1 014,00 JPY
Spread / Highest target 87,4%
Spread / Average Target 87,4%
Spread / Lowest Target 87,4%
EPS Revisions
Managers
NameTitle
Kiichiro Kawada CFO, Director & Managing Executive Director
Naoki Tani Representative Director
Shuzo Watanabe Director & Managing Executive Officer
Shinnosuke Maki Independent Outside Director
Hisaji Agata Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
RAQUALIA PHARMA INC.-24.38%203
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273